Behavioral phenotyping of mouse models of Parkinson's disease

Behavioural Brain Research

Volumn 211, Issue 1, 2010, Pages 1-10

  Taylor, Tonya N ^a,b   Greene, James G ^a   Miller, Gary W ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Behavioral phenotyping; L DOPA; Parkinson's disease

Indexed keywords

DOPAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAM; GASTROINTESTINAL DISEASE; LEARNING; LOCOMOTION; MAZE TEST; MOTOR CONTROL; MOUSE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SLEEP DISORDER; SMELLING DISORDER; STOMACH EMPTYING; TASK PERFORMANCE; TASTE AVERSION; VISUAL SYSTEM FUNCTION; WAKEFULNESS; WORKING MEMORY;

ANIMALS; BEHAVIOR, ANIMAL; BEHAVIORAL RESEARCH; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; PARKINSON DISEASE; PHENOTYPE;

EID: 77952319464     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.03.004     Document Type: Review

References (138)

1. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144.
2. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007, 30:244-250.
3. Jenner P., Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Neurology 2006, 66:S24-36.
4. Meredith G.E., Kang U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 2006, 21:1595-1606.
5. Brooks S.P., Dunnett S.B. Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci 2009, 10:519-529.
6. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-125.
7. Tillerson J.L., Caudle W.M., Reveron M.E., Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 2002, 178:80-90.
8. Rommelfanger K.S., Edwards G.L., Freeman K.G., Liles L.C., Miller G.W., Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 2007, 104:13804-13809.
9. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
10. Colebrooke R.E., Humby T., Lynch P.J., McGowan D.P., Xia J., Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur J Neurosci 2006, 24:2622-2630.
11. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006, 59:591-596.
12. Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 2008, 64(Suppl. 2):S16-29.
13. Olanow C.W., Kieburtz K., Schapira A.H. Why have we failed to achieve neuroprotection in Parkinson's disease?. Ann Neurol 2008, 64(Suppl. 2):S101-S110.
14. Lang A.E., Obeso J.A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004, 3:309-316.
15. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
16. Ziemssen T., Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2007, 13:323-332.
17. Shulman L.M., Taback R.L., Bean J., Weiner W.J. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001, 16:507-510.
18. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E., Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004, 56:173-181.
19. Comella C.L. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep 2003, 3:173-180.
20. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991, 14:153-197.
21. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
22. Tillerson J.L., Caudle W.M., Parent J.M., Gong C., Schallert T., Miller G.W. Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. Behav Brain Res 2006, 172:97-105.
23. Taylor T.N., Caudle W.M., Shepherd K.R., Noorian A., Jackson C.R., Iuvone P.M., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 2009, 29:8103-8113.
24. Grill H.J., Norgren R. The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 1978, 143:263-279.
25. Schallert T., Whishaw I.Q. Two types of aphagia and two types of sensorimotor impairment after lateral hypothalamic lesions: observations in normal weight, dieted, and fattened rats. J Comp Physiol Psychol 1978, 92:720-741.
26. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 1999, 835:18-26.
27. Cameron M.A., Barnard A.R., Lucas R.J. The electroretinogram as a method for studying circadian rhythms in the mammalian retina. J Genet 2008, 87:459-466.
28. Sugawara T., Sieving P.A., Iuvone P.M., Bush R.A. The melatonin antagonist luzindole protects retinal photoreceptors from light damage in the rat. Invest Ophthalmol Vis Sci 1998, 39:2458-2465.
29. Fahn S., Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1:139-154.
30. Langston J.W. MPTP: insights into the etiology of Parkinson's disease. Eur Neurol 1987, 26(Suppl. 1):2-10.
31. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009, 12:826-828.
32. Hwang D.Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., et al. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 2005, 25:2132-2137.
33. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007, 104:1325-1330.
34. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007, 27:8138-8148.
35. Fernagut P.O., Diguet E., Labattu B., Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 2002, 113:123-130.
36. Gispert S., Del Turco D., Garrett L., Chen A., Bernard D.J., Hamm-Clement J., et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 2003, 24:419-429.
37. Plaas M., Karis A., Innos J., Rebane E., Baekelandt V., Vaarmann A., et al. Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice. J Physiol Pharmacol 2008, 59:205-216.
38. Chandran J.S., Lin X., Zapata A., Hoke A., Shimoji M., Moore S.O., et al. Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol Dis 2008, 29:505-514.
39. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
40. Doty R.L., Stern M.B., Pfeiffer C., Gollomp S.M., Hurtig H.I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992, 55:138-142.
41. Tissingh G., Booij J., Bergmans P., Winogrodzka A., Janssen A.G., van Royen E.A., et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 1998, 39:1143-1148.
42. Ward C.D., Hess W.A., Calne D.B. Olfactory impairment in Parkinson's disease. Neurology 1983, 33:943-946.
43. Kranick S.M., Duda J.E. Olfactory dysfunction in Parkinson's disease. Neurosignals 2008, 16:35-40.
44. Ross G.W., Petrovitch H., Abbott R.D., Tanner C.M., Popper J., Masaki K., et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008, 63:167-173.
45. Fleming S.M., Tetreault N.A., Mulligan C.K., Hutson C.B., Masliah E., Chesselet M.F. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 2008, 28:247-256.
46. Nathan B.P., Yost J., Litherland M.T., Struble R.G., Switzer P.V. Olfactory function in apoE knockout mice. Behav Brain Res 2004, 150:1-7.
47. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009, 29:954-963.
48. Doty R.L., Shaman P., Kimmelman C.P., Dann M.S. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984, 94:176-178.
49. Bielsky I.F., Hu S.B., Szegda K.L., Westphal H., Young L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 2004, 29:483-493.
50. Comella C.L. Sleep disorders in Parkinson's disease: an overview. Mov Disord 2007, 22(Suppl. 17):S367-S373.
51. Abbott R.D., Ross G.W., White L.R., Tanner C.M., Masaki K.H., Nelson J.S., et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005, 65:1442-1446.
52. Ondo W.G., Dat Vuong K., Khan H., Atassi F., Kwak C., Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001, 57:1392-1396.
53. Borek L.L., Kohn R., Friedman J.H. Mood and sleep in Parkinson's disease. J Clin Psychiatry 2006, 67:958-963.
54. Dhawan V., Dhoat S., Williams A.J., Dimarco A., Pal S., Forbes A., et al. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J Neurol Sci 2006, 248:158-162.
55. Zesiewicz T.A., Sullivan K.L., Hauser R.A. Nonmotor symptoms of Parkinson's disease. Expert Rev Neurother 2006, 6:1811-1822.
56. Mitchell H.A., Bogenpohl J.W., Liles L.C., Epstein M.P., Bozyczko-Coyne D., Williams M., et al. Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action. Pharmacol Biochem Behav 2008, 91:217-222.
57. Hunsley M.S., Palmiter R.D. Altered sleep latency and arousal regulation in mice lacking norepinephrine. Pharmacol Biochem Behav 2004, 78:765-773.
58. Hunsley M.S., Palmiter R.D. Norepinephrine-deficient mice exhibit normal sleep-wake states but have shorter sleep latency after mild stress and low doses of amphetamine. Sleep 2003, 26:521-526.
59. Monaca C., Boutrel B., Hen R., Hamon M., Adrien J. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003, 28:850-856.
60. Laloux C., Derambure P., Kreisler A., Houdayer E., Brueziere S., Bordet R., et al. MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Exp Brain Res 2008, 186:635-642.
61. Valatx J.L., Bugat R. Genetic factors as determinants of the waking-sleep cycle in the mouse (author's transl). Brain Res. 1974, 69:315-330.
62. Tobler I., Deboer T., Fischer M. Sleep and sleep regulation in normal and prion protein-deficient mice. J Neurosci 1997, 17:1869-1879.
63. Laloux C., Derambure P., Houdayer E., Jacquesson J.M., Bordet R., Destee A., et al. Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice. J Sleep Res 2008, 17:101-110.
64. Dzirasa K., Ribeiro S., Costa R., Santos L.M., Lin S.C., Grosmark A., et al. Dopaminergic control of sleep-wake states. J Neurosci 2006, 26:10577-10589.
65. Edwards L., Quigley E.M., Hofman R., Pfeiffer R.F. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov Disord 1993, 8:83-86.
66. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57:456-462.
67. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003, 2:107-116.
68. Anderson G., Noorian A.R., Taylor G., Anitha M., Bernhard D., Srinivasan S., et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp Neurol 2007, 207:4-12.
69. Wakabayashi K., Takahashi H., Takeda S., Ohama E., Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988, 76:217-221.
70. Braak H., de Vos R.A., Bohl J., Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006, 396:67-72.
71. Singaram C., Ashraf W., Gaumnitz E.A., Torbey C., Sengupta A., Pfeiffer R., et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995, 346:861-864.
72. Tian Y.M., Chen X., Luo D.Z., Zhang X.H., Xue H., Zheng L.F., et al. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Neuroscience 2008, 153:634-644.
73. Bassotti G., Maggio D., Battaglia E., Giulietti O., Spinozzi F., Reboldi G., et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2000, 68:768-770.
74. Whited K.L., Thao D., Lloyd K.C., Kopin A.S., Raybould H.E. Targeted disruption of the murine CCK1 receptor gene reduces intestinal lipid-induced feedback inhibition of gastric function. Am J Physiol Gastrointest Liver Physiol 2006, 291:G156-G162.
75. Li Z.S., Schmauss C., Cuenca A., Ratcliffe E., Gershon M.D. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci 2006, 26:2798-2807.
76. Wang L., Fleming S.M., Chesselet M.F., Tache Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008, 19:873-876.
77. Anitha M., Chandrasekharan B., Salgado J.R., Grouzmann E., Mwangi S., Sitaraman S.V., et al. Glial-derived neurotrophic factor modulates enteric neuronal survival and proliferation through neuropeptide Y. Gastroenterology 2006, 131:1164-1178.
78. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
79. Poewe W. Depression in Parkinson's disease. J Neurol 2007, 254:49-55.
80. Lemke M.R., Fuchs G., Gemende I., Herting B., Oehlwein C., Reichmann H., et al. Depression and Parkinson's disease. J Neurol 2004, 251(Suppl. 6: VI):24-27.
81. Weisskopf M.G., Chen H., Schwarzschild M.A., Kawachi I., Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 2003, 18:646-651.
82. Brown R., Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 1995, 65:61-84.
83. Maricle R.A., Nutt J.G., Valentine R.J., Carter J.H. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995, 45:1757-1760.
84. Czernecki V., Pillon B., Houeto J.L., Pochon J.B., Levy R., Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002, 40:2257-2267.
85. Cummings J.L. Depression and Parkinson's disease: a review. Am J Psychiatry 1992, 149:443-454.
86. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000, 69:308-312.
87. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
88. File S.E., Baldwin H.A., Johnston A.L., Wilks L.J. Behavioral effects of acute and chronic administration of caffeine in the rat. Pharmacol Biochem Behav 1988, 30:809-815.
89. Paine T.A., Jackman S.L., Olmstead M.C. Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 2002, 13:511-523.
90. George S., van den Buuse M., San Mok S., Masters C.L., Li Q.X., Culvenor J.G. Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 2008, 210:788-792.
91. Fukui M., Rodriguiz R.M., Zhou J., Jiang S.X., Phillips L.E., Caron M.G., et al. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci 2007, 27:10520-10529.
92. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988, 31:959-962.
93. Zhu X.R., Maskri L., Herold C., Bader V., Stichel C.C., Gunturkun O., et al. Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci 2007, 26:1902-1911.
94. Vuckovic M.G., Wood R.I., Holschneider D.P., Abernathy A., Togasaki D.M., Smith A., et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008, 32:319-327.
95. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 2001, 155:315-322.
96. Dixon A.K. Ethological strategies for defence in animals and humans: their role in some psychiatric disorders. Br J Med Psychol 1998, 71(Pt 4):417-445.
97. Porsolt R.D., Bertin A., Blavet N., Deniel M., Jalfre M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979, 57:201-210.
98. Cryan J.F., O'Leary O.F., Jin S.H., Friedland J.C., Ouyang M., Hirsch B.R., et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci USA 2004, 101:8186-8191.
99. Skalisz L.L., Beijamini V., Joca S.L., Vital M.A., Da Cunha C., Andreatini R. Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:879-883.
100. Caballol N., Marti M.J., Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007, 22(Suppl. 17):S358-S366.
101. Fuchs G.A., Gemende I., Herting B., Lemke M.R., Oehlwein C., Reichmann H., et al. Dementia in idiopathic Parkinson's syndrome. J Neurol 2004, 251(Suppl. 6: VI):28-32.
102. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
103. Olton D.S. The radial arm maze as a tool in behavioral pharmacology. Physiol Behav 1987, 40:793-797.
104. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006, 26:1343-1354.
105. Schwegler H., Crusio W.E., Lipp H.P., Brust I., Mueller G.G. Early postnatal hyperthyroidism alters hippocampal circuitry and improves radial-maze learning in adult mice. J Neurosci 1991, 11:2102-2106.
106. Prediger R.D., Batista L.C., Medeiros R., Pandolfo P., Florio J.C., Takahashi R.N. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 2006, 202:391-403.
107. Prediger R.D., Aguiar A.S., Rojas-Mayorquin A.E., Figueiredo C.P., Matheus F.C., Ginestet L., et al. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res 2010, 17(2):114-129.
108. Fredriksson A., Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J Neural Transm Park Dis Dement Sect 1994, 7:123-132.
109. Ogawa N., Hirose Y., Ohara S., Ono T., Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 1985, 50:435-441.
110. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 1998, 83:165-175.
111. Mitra N., Mohanakumar K.P., Ganguly D.K. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res Bull 1992, 28:355-364.
112. Mohanakumar K.P., Muralikrishnan D., Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res 2000, 864:281-290.
113. Gupta M., Gupta B.K., Thomas R., Bruemmer V., Sladek J.R., Felten D.L. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci Lett 1986, 70:326-331.
114. Rojo A.I., Cavada C., de Sagarra M.R., Cuadrado A. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Exp Neurol 2007, 208:120-126.
115. Richter F., Hamann M., Richter A. Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J Neurosci Res 2007, 85:681-691.
116. Li X., Yin J., Cheng C.M., Sun J.L., Li Z., Wu Y.L. Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice. Chin Med J (Engl) 2005, 118:1357-1361.
117. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., et al. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 2003, 18:589-600.
118. Schneider J.A. Reserpine antagonism of morphine analgesia in mice. Proc Soc Exp Biol Med 1954, 87:614-615.
119. Unger E.L., Eve D.J., Perez X.A., Reichenbach D.K., Xu Y., Lee M.K., et al. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol Dis 2006, 21:431-443.
120. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
121. Oksman M., Tanila H., Yavich L. Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of l-DOPA. Neuropharmacology 2009, 56:647-652.
122. Yavich L., Oksman M., Tanila H., Kerokoski P., Hiltunen M., van Groen T., et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis 2005, 20:303-313.
123. Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2003, 24:245-258.
124. Fleming S.M., Salcedo J., Hutson C.B., Rockenstein E., Masliah E., Levine M.S., et al. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 2006, 142:1245-1253.
125. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004, 24:9434-9440.
126. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003, 278:43628-43635.
127. Perez F.A., Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005, 102:2174-2179.
128. Gispert S., Ricciardi F., Kurz A., Azizov M., Hoepken H.H., Becker D., et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009, 4:e5777.
129. Zhou H., Falkenburger B.H., Schulz J.B., Tieu K., Xu Z., Xia X.G. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 2007, 3:242-250.
130. Chen L., Cagniard B., Mathews T., Jones S., Koh H.C., Ding Y., et al. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 2005, 280:21418-21426.
131. Manning-Bog A.B., Caudle W.M., Perez X.A., Reaney S.H., Paletzki R., Isla M.Z., et al. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis 2007, 27:141-150.
132. Ardayfio P., Moon J., Leung K.K., Youn-Hwang D., Kim K.S. Impaired learning and memory in Pitx3 deficient aphakia mice: a genetic model for striatum-dependent cognitive symptoms in Parkinson's disease. Neurobiol Dis 2008, 31:406-412.
133. Mooslehner K.A., Chan P.M., Xu W., Liu L., Smadja C., Humby T., et al. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol Cell Biol 2001, 21:5321-5331.
134. Tanila H., Bjorklund M., Riekkinen P. Cognitive changes in mice following moderate MPTP exposure. Brain Res Bull 1998, 45:577-582.
135. Litteljohn D., Mangano E., Shukla N., Hayley S. Interferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience 2009, 164:1894-1906.
136. Silva R.H., Abilio V.C., Torres-Leite D., Bergamo M., Chinen C.C., Claro F.T., et al. Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. Behav Brain Res 2002, 132:171-177.
137. Freichel C., Neumann M., Ballard T., Muller V., Woolley M., Ozmen L., et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging 2007, 28:1421-1435.
138. Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme G.A., et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003, 12:2277-2291.